ARTICLE | Company News
SciClone cancer news
November 2, 2009 8:00 AM UTC
SciClone will restructure and reduce headcount by seven (17%) to 34, with cuts primarily in research and development. In October, SciClone discontinued a Phase II of RP101 to treat advanced pancreatic...